<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709458</url>
  </required_header>
  <id_info>
    <org_study_id>TBX-2400-001</org_study_id>
    <nct_id>NCT04709458</nct_id>
  </id_info>
  <brief_title>Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis</brief_title>
  <official_title>A Phase I Study to Assess the Safety and Early Efficacy of TBX-2400 in Enhancing Engraftment in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of Acute Myelogenous Leukemia or Myelofibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiga Biotechnologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiga Biotechnologies, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of allogeneic stem cell transplantation with TBX-2400 in adult subjects with&#xD;
      Acute Myelogenous Leukemia (AML) or Myelofibrosis (MF).&#xD;
&#xD;
      The donor cells are exposed to a protein that has been shown in the laboratory to improve the&#xD;
      ability of the donor cells to make blood and immune cells after transplant. Exposure of the&#xD;
      donor cells to this protein does not modify the genes in the cells in any way.&#xD;
&#xD;
      This study has two goals. The first goal is to find out if transplant with TBX-2400 is safe.&#xD;
      The second goal is to find out what effects TBX-2400 stem cells have on time to engraftment&#xD;
      in adult subjects with AML or MF.&#xD;
&#xD;
      The study hypothesis is that TBX-2400 cells will shorten the time to immune reconstitution&#xD;
      after transplant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">October 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events according to NCI-CTCAE Version 5.0</measure>
    <time_frame>Two years</time_frame>
    <description>Adverse events from subject reporting or other assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant engraftment</measure>
    <time_frame>1 year</time_frame>
    <description>Assessment of transplant engraftment will include absolute neutrophil count, untransfused platelet count and donor chimerism</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immune reconstitution as measured by CD3+ cell count</measure>
    <time_frame>Up to Day 360</time_frame>
    <description>Immune reconstitution as measured by CD3+ cell count &gt; 300/μL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin (IgA) levels</measure>
    <time_frame>Up to Day 360</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunoglobulin (IgM) levels</measure>
    <time_frame>Up to Day 360</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell Engraftment</measure>
    <time_frame>Up to Day 360</time_frame>
    <description>CD45 RA versus RO at 3, 6, 9 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of secondary graft failure</measure>
    <time_frame>Two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-Related Mortality (TRM)</measure>
    <time_frame>100 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the World Health Organisation Five Wellbeing Index</measure>
    <time_frame>Up to day 360</time_frame>
    <description>QoL assessed at 3, 6, 9 and 12 months (World Health Organization [WHO] Five Wellbeing Index).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Myelofibrosis</condition>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>TBX-2400 treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous infusion of TBX-2400</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TBX-2400</intervention_name>
    <description>Hematopoietic stem cells transplantation</description>
    <arm_group_label>TBX-2400 treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. For crAML: AML with ≥5% blasts (either by morphology or by multi-parameter flow&#xD;
             cytometry [MFC]) in a marrow aspirate obtained within 21 days of enrollment in the&#xD;
             trial, and following the administration of at least two prior courses of chemotherapy;&#xD;
&#xD;
          2. For MF: primary MF or MF that has progressed from a myeloproliferative disease.&#xD;
             Dynamic International Prognostic Scoring System (DIPSS)-plus to be utilized to support&#xD;
             the inclusion of MF subjects at screening;&#xD;
&#xD;
          3. Subject undergoing allogeneic stem cell transplantation on the decision of&#xD;
             transplanting physician;&#xD;
&#xD;
          4. Signed informed consent of donor and recipient;&#xD;
&#xD;
          5. Subjects of ≥ 18 years of age (no upper age limit);&#xD;
&#xD;
          6. Donor agrees to donate bone marrow-derived or mobilized peripheral blood stem cells;&#xD;
&#xD;
          7. Subjects with Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2;&#xD;
&#xD;
          8. Adequate pulmonary function with Diffusing Capacity for Carbon Monoxide (DLCO) &gt; 50;&#xD;
&#xD;
          9. Women of childbearing potential (WOCBP) must agree to follow instructions for&#xD;
             method(s) of contraception (e.g. sterilization, hormone implants, hormone injections,&#xD;
             intrauterine devices, or vasectomized partner with combined use of condom and/or birth&#xD;
             control pills) from screening until 6 months after TBX-2400 transplantation;&#xD;
&#xD;
         10. Able to adhere to all trial treatments and procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous stem cell transplantation;&#xD;
&#xD;
          2. For MF: Blasts &gt; 10% in a marrow aspirate obtained within 30 days of screening;&#xD;
&#xD;
          3. Renal function: serum creatinine &gt; 1.5 x Upper Limit of Normal (ULN);&#xD;
&#xD;
          4. Hepatic function: impaired synthetic function as indicated by a serum fibrinogen below&#xD;
             the normal limit. Aspartate transaminase/alanine transaminase (AST/ALT) &gt; 3.0 x ULN.&#xD;
             Bilirubin, &gt; 1.5 x ULN;&#xD;
&#xD;
          5. Cardiac function: ejection fraction &lt; 45% as determined by echocardiography;&#xD;
&#xD;
          6. Prior malignancy active within previous three years - except for locally curable&#xD;
             cancers such as cutaneous basal or squamous cell cancer, superficial bladder cancer,&#xD;
             carcinoma in situ of cervix or breast, or carcinoma in situ of the prostate;&#xD;
&#xD;
          7. Positive pregnancy test or breastfeeding for women of childbearing age;&#xD;
&#xD;
          8. Serologic evidence of chronic Hepatitis B virus infection or Hepatitis C exposure;&#xD;
&#xD;
          9. Known history of positive test for Human Immunodeficiency Virus (HIV) or known&#xD;
             Acquired Immunodeficiency Syndrome (AIDS);&#xD;
&#xD;
         10. Hypersensitivity to any trial medication (including the preparative regimen, TBX-2400&#xD;
             treatment and any prophylaxis or other medication planned);&#xD;
&#xD;
         11. Presence of a serious or uncontrolled medical disorder that, in the opinion of the&#xD;
             Investigator, may increase the risk associated with trial participation or trial drug&#xD;
             administration, impair the ability of the participant to receive protocol therapy, or&#xD;
             interfere with interpretation of trial results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Bacigalupo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unit for Hematology and BMT, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vivienne Margolis, B.Sc</last_name>
    <phone>+972-4639634</phone>
    <email>vmargolis@taigabiotech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yosef Refaeli, Ph.D</last_name>
    <phone>+1-720-859-3547</phone>
    <email>refaeli@taigabiotech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Centre Zagreb</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <contact>
      <last_name>Nadira Durakovic, MD, PhD</last_name>
      <phone>+385-989611829</phone>
      <email>nadira.durakovic@mef.hr</email>
    </contact>
    <investigator>
      <last_name>Nadira Durakovic, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Simona Sica, MD</last_name>
      <phone>TBA</phone>
      <email>Simona.sica@unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Simona Sica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Croatia</country>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelofibrosis</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Allogeneic stem cell transplant</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Myeloproliferative disorders</keyword>
  <keyword>Primary myelofibrosis</keyword>
  <keyword>Bone Marrow Cancer</keyword>
  <keyword>Bone Marrow Transplant</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

